IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT05353530
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells — BIOLOGICAL
    Single dose of 8R-70CAR T cells administered IV

Study Details

This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma

Key Dates

Start date
Jul 25, 2023
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2042

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 8R-70CAR T cells
    Cohort 1 will receive 1 x 10\^6 cells/kg. Cohort 2 will receive 1 x 10\^7 cells/kg. Cohort 3 will receive 1 x 10\^8 cells/kg. Cohort 4 will receive Cy/Flu + CAR T cells at established maximum tolerated dose.

Primary Outcome Measure

Safety of 8R-70CAR T-cell therapy in adult patients with de novo CD70+ GBM [ Time Frame: 28 days post-infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Florida HealthGainesvilleFlorida32608
Phuong Deleyrolle, RN
[email protected]
352-273-5519
Ashley Ghiaseddin, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gainesville, FL

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Florida Health· Gainesville, FL

Related Studies